Cargando…
Leukemia propagating cells in Philadelphia chromosome-positive ALL: a resistant phenotype with an adverse prognosis
BACKGROUND: Targeted therapy has revolutionized the management of Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL); however, relapse still occurs because of the presence of quiescent stem cells, termed leukemia propagating cells (LPCs). This study aimed to assess the phenoty...
Autores principales: | El-Menshawy, Nadia, Abd-Aziz, Sherin M., Elkhamisy, Enas M, Ebrahim, Mohammed A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Korean Society of Hematology; Korean Society of Blood and Marrow Transplantation; Korean Society of Pediatric Hematology-Oncology; Korean Society on Thrombosis and Hemostasis
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6021579/ https://www.ncbi.nlm.nih.gov/pubmed/29963520 http://dx.doi.org/10.5045/br.2018.53.2.138 |
Ejemplares similares
-
Ruxolitinib/nilotinib cotreatment inhibits leukemia-propagating cells in Philadelphia chromosome-positive ALL
por: Kong, Yuan, et al.
Publicado: (2017) -
CD58; leucocyte function adhesion-3 (LFA-3) could be used as a differentiating marker between immune and non-immune thyroid disorders
por: El Menshawy, Nadia, et al.
Publicado: (2018) -
PB1757: VARIANT PHILADELPHIA CHROMOSOME IN ALL
por: Bouayed Abdelmoula, N., et al.
Publicado: (2022) -
High Incidence of Philadelphia Chromosome-Like Acute Lymphoblastic Leukemia (Ph-like ALL) in Older Adults with B-ALL
por: Tasian, Sarah K, et al.
Publicado: (2016) -
What Is the Role of HSCT in Philadelphia-Chromosome–Positive and Philadelphia-Chromosome–Like ALL in the Tyrosine Kinase Inhibitor Era?
por: Vettenranta, Kim, et al.
Publicado: (2022)